Tenofovir is Associated With Higher Risk of Kidney Function Decline Than Entecavir in Patients With Chronic Hepatitis B

Clicks: 154
ID: 273317
2021
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Of the antiviral agents currently available to patients with chronic hepatitis B (CHB), entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are 2 of 3 first-line agents.1-3 Given the well-known renal and bone toxicity associated with TDF,4 major international hepatitis B vi …
Reference Key
cy2021clinicaltenofovir Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jung CY;Kim HW;Ahn SH;Kim SU;Kim BS;;
Journal clinical gastroenterology and hepatology : the official clinical practice journal of the american gastroenterological association
Year 2021
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/34029751
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE pubmed abstract nih national institutes of health national library of medicine pmid:34029751 doi:10.1016/j.cgh.2021.05.032 chan-young jung hyung woo kim beom seok kim

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.